Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the target of unusually large options trading activity on Wednesday. Investors bought 1,002 put options on the stock. This is an increase of approximately 1,791% compared to the average daily volume of 53 put options.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Robert W. Baird reduced their target price on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th. UBS Group cut their price objective on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating for the company in a report on Friday, March 21st. Stifel Nicolaus set a $5.00 price target on shares of Maravai LifeSciences in a report on Friday, March 21st. Craig Hallum cut their price target on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Finally, Morgan Stanley cut their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, March 25th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Maravai LifeSciences has an average rating of "Hold" and an average price target of $6.64.

Maravai LifeSciences Trading Up 4.7%

Shares of Maravai LifeSciences stock traded up $0.13 during trading on Thursday, reaching $2.89. The company's stock had a trading volume of 2,308,182 shares, compared to its average volume of 2,292,007. Maravai LifeSciences has a 52-week low of $1.67 and a 52-week high of $10.03. The company has a market cap of $735.97 million, a price-to-earnings ratio of -2.54 and a beta of 0.28. The firm's 50-day moving average is $2.25 and its two-hundred day moving average is $3.13. The company has a quick ratio of 5.17, a current ratio of 5.96 and a debt-to-equity ratio of 0.60.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The business had revenue of $46.85 million during the quarter, compared to analysts' expectations of $44.01 million. Maravai LifeSciences had a negative return on equity of 12.91% and a negative net margin of 67.14%. The firm's revenue was down 26.9% on a year-over-year basis. On average, sell-side analysts anticipate that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MRVI. Strs Ohio bought a new position in Maravai LifeSciences in the first quarter worth approximately $429,000. McAdam LLC acquired a new position in Maravai LifeSciences during the 1st quarter valued at about $31,000. Jane Street Group LLC boosted its holdings in Maravai LifeSciences by 1,463.1% in the first quarter. Jane Street Group LLC now owns 380,403 shares of the company's stock worth $841,000 after acquiring an additional 356,067 shares in the last quarter. Ascent Group LLC acquired a new position in shares of Maravai LifeSciences during the first quarter valued at about $41,000. Finally, Clearline Capital LP increased its stake in Maravai LifeSciences by 9.6% during the 1st quarter. Clearline Capital LP now owns 205,339 shares of the company's stock valued at $454,000 after purchasing an additional 18,000 shares in the last quarter. 50.25% of the stock is owned by hedge funds and other institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.